NeuroproteXeon

NeuroproteXeon is a clinical-stage pharmaceutical company developing proprietary xenon-based therapies, delivered through a patented inhalation device, to prevent brain cell death following acute neurological injury. NP is currently preparing for Phase III clinical trials in out-of-hospital cardiac arrest (OHCA).